Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Pharmacol ; 236(3): 467-76, 1993 Jun 04.
Article in English | MEDLINE | ID: mdl-8102972

ABSTRACT

The specific binding of the agonists [3H]clonidine and [3H]UK 14304 (bromoxidine) and of the antagonist [3H]RX 821002 (2-metoxy idazoxan) to rat brain membranes, as well as clonidine-induced mydriasis, clonidine-induced inhibition of brain (3,4-dihydroxyphenylalaninme) DOPA synthesis and clonidine-induced inhibition of twitch responses in the vas deferens, was used to evaluate the density and sensitivity of central and peripheral alpha 2-adrenoceptors after prolonged activation of the cholinergic system. Acute (12 h), short-term (4 days) or chronic (7-18 days) treatment with the cholinesterase inhibitors neostigmine (0.1 mg/kg), physostigmine (0.1 mg/kg) and diisopropylfluorophosphate (2 mg/kg) and with the muscarinic receptor agonist pilocarpine (10 mg/kg) did not alter the density of brain alpha 2-adrenoceptors. In contrast, various functional responses mediated by central and peripheral alpha 2-adrenoceptors were potentiated after the repeated treatments. Thus, the inhibitory alpha 2-autoreceptor that modulates the synthesis of brain noradrenaline and the central postsynaptic inhibitory alpha 2-adrenoceptor that induces mydriasis displayed greater responses in vivo after chronic treatment with neostigmine or pilocarpine. These treatments also increased the sensitivity of peripheral presynaptic alpha 2-adrenoceptors in the vas deferens. The results indicate that prolonged activation of central and peripheral cholinergic pathways results in up-regulation of alpha 2-adrenoceptor function without apparent increases in receptor density.


Subject(s)
Brain/drug effects , Cholinesterase Inhibitors/pharmacology , Pilocarpine/pharmacology , Receptors, Adrenergic, alpha/drug effects , Vas Deferens/drug effects , Adrenergic alpha-Agonists/metabolism , Adrenergic alpha-Agonists/pharmacology , Adrenergic alpha-Antagonists/metabolism , Adrenergic alpha-Antagonists/pharmacology , Animals , Binding Sites , Brain/metabolism , Brimonidine Tartrate , Cholinesterase Inhibitors/administration & dosage , Clonidine/metabolism , Clonidine/pharmacology , Dioxanes/metabolism , Dioxanes/pharmacology , Idazoxan/analogs & derivatives , In Vitro Techniques , Isoflurophate/pharmacology , Male , Neostigmine/pharmacology , Physostigmine/pharmacology , Pilocarpine/metabolism , Quinoxalines/metabolism , Quinoxalines/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Adrenergic, alpha/physiology , Tyrosine 3-Monooxygenase/antagonists & inhibitors , Vas Deferens/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...